

## Repurposing Drugs for Covid-19

**Amol Bhosale\***

Department of Pharmaceutical Sciences, India

**\*Corresponding Author:** Amol Bhosale, Department of Pharmaceutical Sciences, India.**Received:** April 19, 2020**Published:** June 01, 2020© All rights are reserved by **Amol Bhosale**.

Coronavirus disease (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2). COVID-19 is the next generation of the SARS-CoV virus. It has a zoonotic origin. Coronavirus genetically clusters with genus Betacoronavirus, in subgenus Sarbecovirus. Common symptoms include fever, cough and shortness of breathing. In this condition, there is an urgent need for an effective treatment to treat COVID-19 infection. The decrease in the order of community transmission is the global challenge. The discovery of new vaccine for COVID-19 is a lengthy procedure. For the current COVID-19 world pandemic situation, repositioning of old drugs for the use of antiviral treatment is an interesting method in this emergency condition.

The primary target is to stop the RNA replication and transcription of this virus. The replication cycle is stopped using the finding routes of replication. There are different inhibitors of COVID-19 replication. It also includes kinases inhibitors, protease inhibitors and also endosomal pH regulators. The drugs increase the pH in organelles like lysosomes, endosomes, Golgi vesicles of the virus. This is responsible for its antiviral activity. These drugs mainly inhibit the entry of virus into their host cell.

Chloroquine and Hydroxychloroquine is the anti-parasitic drug which was used against malaria disease. It has also been used against Zika virus and influenza A H5N1. Chloroquine is a weak base that becomes entrapped in membrane-enclosed low pH organelles, interfering with their acidification. In malaria-causing Plasmodium parasites, Chloroquine accumulates in the digestion. If the Chloroquine and Hydroxychloroquine derivatives were applied against the COVID-19 virus, the result may be shown like the lysosomal pH is increased and culture media restricted, protease inhibition (proteolysis) is carried out. Replication of virus requires low pH and if pH is destroyed the release of the viral genome is prohibited. Chloroquine may also affect on virion assembly of Golgi apparatus and endoplasmic reticulum.

Similarly, antiviral medications like Lopinavir/ritonavir, Remdesivir were studied against COVID-19. These are active medications against viral replication or viral infection. It is an adenosine analogue, which is incorporated into nascent viral RNA chains and results in premature termination. Remdesivir

was not FDA approved but it was used against the Ebola virus. Ivermectin may have a good effect like it has stopped the growth of viral colonies. (this test was not performed on the human). The drugs like chlorpromazine can inhibit the entry of COVID-19 into the host cells.

Vitamin C (Ascorbic acid) consists of antioxidant properties. It doesn't have a direct effect on COVID-19 but it regulates or maintains the endosomal pH regulation in the lysosomes.

Studies also found that antibiotics like azithromycin used against COVID-19. Azithromycin was also used for pneumonia diseases, which happened because of bacterial infection. Antiviral action of Azithromycin is not known. But some study finds that it may have immunomodulatory properties. Which might be beneficial against pulmonary viral infections. It is also stable in acidic conditions [1-4].

**Bibliography**

1. Tony Y Hu., *et al.* "Insights from nanomedicine into chloroquine efficiency against COVID-19". *Nature Nanotechnology* 15.4 (2020): 247-249.
2. Rosa SGV and Santos WC. "Clinical trials on drug repositioning for COVID-19 treatment". *Revista Panamericana de Salud Pública* 44 (2020): e40.
3. Bhumi Shah., *et al.* "In silico studies on therapeutic agents for COVID-19: Drug repurposing approach". *Life Sciences* 252 (2020).
4. Elsevier BV. "Fighting viruses with antibiotics: an overlooked path". *International Journal of Antimicrobial Agents* 48.4 (2016): 349-352.

**Assets from publication with us**

- Prompt Acknowledgement after receiving the article
- Thorough Double blinded peer review
- Rapid Publication
- Issue of Publication Certificate
- High visibility of your Published work

**Website:** [www.actascientific.com/](http://www.actascientific.com/)**Submit Article:** [www.actascientific.com/submission.php](http://www.actascientific.com/submission.php)**Email us:** [editor@actascientific.com](mailto:editor@actascientific.com)**Contact us:** +91 9182824667